Search

State

Industry

Company

BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

COLLABORATION AGREEMENT

Acorda Therapeutics Inc

Certain portions of this have been omitted pursuant to a request for confidentiality. Such omitted portions, which are marked with brackets [ ] and an asterisk*, have been separately filed with the Commission. COLLABORATION AGREEMENT by and between TEVA PHARMACEUTICAL INDUSTRIES LTD. and ACORDA THERAPEUTICS, INC. COLLABORATION AGREEMENT THIS COLLABORATION AGREEMENT (this “ Agreement ”) is made as

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CONFIDENTIAL CLINICAL

Shockwave Medical, Inc.

CONFIDENTIAL CLINICAL COLLABORATION AGREEMENT This Clinical Collaboration Agreement (this Agreement ), made as of August 16, 2018 (the Effective Date ), is by and between SpringWorks Subsidiary 3, PBC, a public benefit corporation organized under the laws of Delaware ( SpringWorks ), and BeiGene, Ltd., a corporation organized under the laws of the Cayman Islands having its principal addre

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

adap_Ex10_1 CERTAIN CONFIDENTIAL

Vanda Pharmaceuticals Inc.

adap_Ex10_1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED CONFIDENTIAL FINAL COLLABORATION AGREEMENT BETWEEN ADAPTIMMUNE LIMITED AND AIS OPERATING CO., INC. CONFIDENTIAL FINAL TABLE OF CONTENTS Article Page ARTICLE 1 DEFINITIONS 1 ARTICLE 2 GOVERNA

SERVICES-MANAGEMENT SERVICES

2013Q3 February

Advisory Board Co

2013Q3 February 5, 2014 Robert W. Musslewhite Chief Executive Officer 2445 M Street NW Washington DC 20037 Re: Collaboration Agreement, dated as of February 6, 2007, by and between The Corporate Executive Board Company and The Advisory Board Company (as previously amended, the “Collaboration Agreement”) Dear Robert: This letter confirms that The Corporate Executive Board Company (“CEB”) and The A

SERVICES-MANAGEMENT SERVICES

Collaboration Agreement

Advisory Board Co

T HE A DVISORY B OARD C OMPANY 2445 M. STREET, NW WASHINGTON, DC 20037 TELEPHONE 202-266-5600 FACSIMILE 202-266-5700 November 7, 2011 Thomas L. Monahan, III Chairman of the Board and Chief Executive Officer The Corporate Executive Board Company 1919 North Lynn Street Arlington, VA 22209 Re: Collaboration Agreement, dated as of February 6, 2007, by and between The Corporate Executive Board Company

PHARMACEUTICAL PREPARATIONS

Second Closing Letter

Allergan Finance Llc

SECOND CLOSING LETTER Second Closing Letter B February 10, 2012 Watson Pharmaceuticals, Inc. (on behalf of Coventry Acquisition, LLC) 311 Bonnie Circle Corona, CA 92880 Attention: David A. Buchen, Executive Vice President, General Counsel, and Secretary RE: Second Closing under the March 3, 2010 Purchase and Collaboration Agreement Dear Mr. Buchen: I write in reference to Section 7.4 of the Purcha

SERVICES-MANAGEMENT SERVICES

exv10w1 The Advisory Board

Advisory Board Co

exv10w1 The Advisory Board Company 2445 M. STREET, NW WASHINGTON, DC 20037 TELEPHONE 202-266-6696 Robert Musslewhite FACSIMILE 202-266-6633 February 4, 2010 Chief Executive Officer Thomas L. Monahan, III Chairman of the Board and Chief Executive Officer The Corporate Executive Board Company 1919 North Lynn Street Arlington, VA 22209 Re: Collaboration Agreement, dated as of February 6, 2007, by an

PHARMACEUTICAL PREPARATIONS

Blueprint Certain identified

Rattler Midstream Lp

Blueprint Certain identified information has been excluded from the document because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDED AND RESTATED COLLABORATION AGREEMENT THIS AMENDED AND RESTATED COLLABORATION AGREEMENT (the Agreement ) is dated as of June 19, 2019 by and between Checkpoint Therapeutics, Inc., a Delaware corporation organized

PHARMACEUTICAL PREPARATIONS

STRATEGIC COLLABORATION AGREEMENT

Nektar Therapeutics

nktr-ex101_104.htm STRATEGIC COLLABORATION AGREEMENT BY AND BETWEEN Nektar Therapeutics AND Bristol-Myers Squibb Company DATED FEBRUARY 13, 2018 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. TABLE OF CONTENTS Article 1 DEFINITIONS 1 Articl

PHARMACEUTICAL PREPARATIONS

CLINICAL TRIAL COLLABORATION AGREEMENT

Nektar Therapeutics

nktr-ex101_8.htm ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 CLINICAL TRIAL COLLABORATION AGREEMENT This Clinical Trial Collaboration Agreement (the “ Agreement ”) is made and entered into effective as of September 21, 2016 (the “ Effective Date ”) by and between Nektar Thera